Technical Analysis for ELOX - Eloxx Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 4.72 2.61% 0.12
ELOX closed up 2.61 percent on Friday, November 22, 2019, on 50 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical ELOX trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Crossed Above 50 DMA Bullish 0.00%
MACD Bullish Signal Line Cross Bullish 0.00%
Wide Bands Range Expansion 0.00%
Fell Below 20 DMA Bearish 2.61%
Fell Below 50 DMA Bearish 2.61%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 2.61%
New Uptrend Bullish 2.61%
Inside Day Range Contraction 2.61%
Wide Bands Range Expansion 2.61%

Older signals for ELOX ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Eloxx Pharmaceuticals, Inc. (ELOX) is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. These premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. Read-through therapeutic development is focused on extending mRNA half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. Eloxx’s lead product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in the early stages of clinical development focusing on cystic fibrosis and cystinosis. ELX-02 is an investigational drug that has not been approved by any global regulatory body. Eloxx is headquartered in Waltham, MA, with R&D operations in Rehovot, Israel.
Biopharmaceutical Biology Molecular Biology Genetics Gene Expression Cystic Fibrosis Genetic Diseases Molecular Genetics Messenger RNA Genetic Code Protein Biosynthesis Rare And Ultra Rare Diseases
Is ELOX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 16.83
52 Week Low 2.87
Average Volume 232,373
200-Day Moving Average 8.5449
50-Day Moving Average 4.5673
20-Day Moving Average 4.7573
10-Day Moving Average 4.412
Average True Range 0.6803
ADX 24.98
+DI 26.7643
-DI 16.2228
Chandelier Exit (Long, 3 ATRs ) 5.9591
Chandelier Exit (Short, 3 ATRs ) 4.9109
Upper Bollinger Band 6.9449
Lower Bollinger Band 2.5697
Percent B (%b) 0.49
BandWidth 91.968133
MACD Line -0.0082
MACD Signal Line -0.0088
MACD Histogram 0.0006
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.50
Resistance 3 (R3) 5.50 5.23 5.37
Resistance 2 (R2) 5.23 5.03 5.23 5.33
Resistance 1 (R1) 4.98 4.91 5.10 4.98 5.28
Pivot Point 4.71 4.71 4.78 4.72 4.71
Support 1 (S1) 4.46 4.52 4.59 4.46 4.16
Support 2 (S2) 4.19 4.39 4.20 4.11
Support 3 (S3) 3.94 4.19 4.07
Support 4 (S4) 3.94